Qlife puts development of two-in-one test on hold
Today, Qlife announces that a delay in finalizing the development of the two-in-one test for influenza and SARS-CoV-2 virus assay, and associated technical adjustment in the Egoo optics, means that this project has been put on hold. The implications of the development delay are that the clinical trial cannot be finalized before end of 2022, which in turn means that the 3[rd] payment will be cancelled by FIND under the project terms.In December 2021, Qlife signed an agreement with FIND for $ 3.45 million for a 12-month project with the goal of developing a new and cost-effective two-in-one